Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial-Reference-Cited by-同舟云学术

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

Published:2020-07 Issue:7 Volume:8 Page:582-593
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Cherney David Z I,Dekkers Claire C J,Barbour Sean J,Cattran Daniel,Abdul Gafor Abdul Halim,Greasley Peter J,Laverman Gozewijn D,Lim Soo Kun,Di Tanna Gian Luca,Reich Heather N,Vervloet Marc G,Wong Muh Geot,Gansevoort Ron T,Heerspink Hiddo J L

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference29 articles.

1. Canagliflozin slows progression of renal function decline independently of glycemic effects;Heerspink;J Am Soc Nephrol,2017

2. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

3. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

4. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019

5. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial;Mosenzon;Lancet Diabetes Endocrinol,2019

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of dapagliflozin in children with kidney disease: real-world data;Pediatric Nephrology;2024-08-06

2. Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world;Frontiers in Pharmacology;2024-08-05

3. Dapagliflozin for the primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy: design of the multi-center phase II randomized PROTECT trial;2024-07-24

4. Sodium glucose transporter 2 inhibitors: Will these drugs benefit non‐diabetic veterinary patients with cardiac and kidney diseases?;Journal of Veterinary Pharmacology and Therapeutics;2024-07-13

5. Progress of SGLT2 inhibitors in the treatment of common immune-related nephropathies;International Urology and Nephrology;2024-07-04